Future of Gilead Sciences | Quantumrun

Future of Gilead Sciences

Gilead Sciences is a US biopharmaceutical company that develops, commercializes, and discovers therapeutics. For many years since the company was established, it focused mainly on antiviral drugs used in the treatment of influenza, HIV, hepatitis B, and hepatitis C.

Home Country: 
United States
Industry: 
Pharmaceuticals
Industry vulnerability to disruption: 

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations. However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.
*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.
*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.
*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.
*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.

Total patents held: 
479
Ranking List: 
38
Ranking List: 
2017 Quantumrun Global 1000
31
Ranking List: 
2017 Quantumrun US 500
5
Ranking List: 
2017 Quantumrun Silicon Valley 100
Market Revenue Country: 
Market country 
United States
Revenue from country 
0.64
Prod/Serv name revenue: 
Prod/Serv name: 
HCV
Prod/Serv name: 
HIV and other antivirals
Prod/Serv name: 
Other products
Founded: 
1987
Company Name: 
Gilead Sciences
Sector: 
Revenue: 
30390000000
3y average revenue: 
29306333333
Operating expenses: 
12757000000
3y average expenses: 
16031000000
Company profile data note: 
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.
Global employee count: 
9000
Number of domestic locations: 
6
Funds in reserve: 
8229000000
Investment into R&D: 
5100000000
create term: 
#38 | 2017 Quantumrun Global 1000
#31 | 2017 Quantumrun US 500
#5 | 2017 Quantumrun Silicon Valley 100

Gilead Sciences is a US biopharmaceutical company that develops, commercializes, and discovers therapeutics. For many years since the company was established, it focused mainly on antiviral drugs used in the treatment of influenza, HIV, hepatitis B, and hepatitis C.

Home country:
United States
Sector:
Health Care
Industry:
Pharmaceuticals
Website:
Founded:
1987
Global employee count:
9,000

Financial Health

Revenue
$30,390,000,000 USD
3y average revenue
$29,306,333,333 USD
Operating expenses
$12,757,000,000 USD
3y average expenses
$16,031,000,000 USD
Funds in reserve
$8,229,000,000 USD
#1 Market country
United States
% of revenue from country #1
0.64%

Innovation assets and Pipeline

Investment into R&D
$5,100,000,000 USD
Total patents held
479
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.

Disruption Vulnerability

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations. However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.
*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.
*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.
*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.
*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.